A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs

• Үндсэн зохиолчид: Itzel Condado-Morales (Зохиогч), Fabian Dingfelder (Зохиогч), Isabel Waibel (Зохиогч), Oliver M. Turnbull (Зохиогч), Bhargav Patel (Зохиогч), Zheng Cao (Зохиогч), Jais Rose Bjelke (Зохиогч), Susanne Nedergaard Grell (Зохиогч), Anja Bennet (Зохиогч), Alissa M. Hummer (Зохиогч), Matthew I. J. Raybould (Зохиогч), Charlotte M. Deane (Зохиогч), Thomas Egebjerg (Зохиогч), Nikolai Lorenzen (Зохиогч), Paolo Arosio (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Engineered antibody formats, such as antibody fragments and bispecifics, have the potential to offer improved therapeutic efficacy compared to traditional full-length monoclonal antibodies (mAbs). However, the translation of these non-natural molecules into successful therapeutics can be hampered by...